How COVID-19 Testing Demand Threw off Thermo Fisher’s Acquisition of Qiagen
Health Advances
SEPTEMBER 18, 2020
. By Aaron J. Dy, Ph.D., Senior Analyst and Donna Hochberg, Ph.D., Partner. On March 3 rd , Thermo Fisher Scientific (“Thermo Fisher”) announced plans to acquire Qiagen for $11.5B, and by mid-July, the offer grew to $12.5B as COVID-19 increased demand for testing supplies that both companies offer. Then the deal fell apart as only 47% of Qiagen shares were tendered by the Aug. 10 deadline, well short of the two-thirds threshold required to complete the deal.
97 
Let's personalize your content